Prevalence of Lung Cancer Screening in the US, 2022

Louise M Henderson; I-Hsuan Su; M Patricia Rivera; Joyce Pak; Xiaomeng Chen; Daniel S Reuland; Jennifer L Lund

doi:10.1001/jamanetworkopen.2024.3190

Prevalence of Lung Cancer Screening in the US, 2022

JAMA Netw Open. 2024 Mar 4;7(3):e243190. doi: 10.1001/jamanetworkopen.2024.3190.

Authors

Louise M Henderson^{1

2}, I-Hsuan Su³, M Patricia Rivera⁴, Joyce Pak³, Xiaomeng Chen³, Daniel S Reuland^{2

5}, Jennifer L Lund^{2

3}

Affiliations

¹ Department of Radiology, University of North Carolina at Chapel Hill.
² Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill.
³ Department of Epidemiology, University of North Carolina at Chapel Hill.
⁴ Department of Medicine, University of Rochester Medical Center, Rochester, New York.
⁵ Department of Medicine, University of North Carolina at Chapel Hill.

No abstract available

Plain language summary

This cross-sectional study compares lung cancer screening prevalence in 2022 among individuals eligible by 2021 vs 2013 criteria by sociodemographics and state.

MeSH terms

Early Detection of Cancer*
Humans
Lung Neoplasms* / diagnosis
Lung Neoplasms* / epidemiology
Prevalence

Plain language summary

MeSH terms

Grants and funding